Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycosylation-dependent cell adhesion molecule 1 (GLYCAM1) is a mucin-like proteoglycan ligand predominantly expressed on high endothelial venules in lymphoid tissues, where it presents O-linked carbohydrates that serve as ligands for L-selectin on leukocytes, facilitating the exit of naïve lymphocytes from the bloodstream into lymphoid organs. GLYCAM1 is also known to be hormonally regulated and expressed in mammary epithelial cells during lactation, where it is found in milk in a carbohydrate-modified form that does not bind L-selectin, suggesting tissue- and context-dependent biological roles. Functionally, GLYCAM1 mediates lymphocyte homing and trafficking and plays a regulatory role in monocyte entry into tissues such as the optic nerve head. It belongs to the class of mucin-like cell adhesion molecules but lacks a transmembrane region and appears as a soluble protein or, in some tissues, a milk mucin complex component. There are no drugs or therapeutic interventions known to target GLYCAM1 directly, and it is not currently employed as a clinical biomarker or druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosylation-dependent cell adhesion molecule 1 (GLYCAM1).